Your browser doesn't support javascript.
loading
VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?
le Noble, Ferdinand A C; Mourad, Jean-Jacques; Levy, Bernard I; Struijker-Boudier, Harry A J.
Afiliación
  • le Noble FAC; Department of Cell and Developmental Biology, Institute of Zoology (ZOO), Karlsruhe Institute of Technology (KIT), Germany (F.A.C.l.N.).
  • Mourad JJ; Department of Internal Medicine, Hôpital Franco-Britannique, Levallois-Perret, France (J.-J.M.).
  • Levy BI; Université Paris Cité, INSERM, PARCC, France (B.L.L.).
  • Struijker-Boudier HAJ; Department of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht, Maastricht University, Netherlands (H.A.J.S.-B.).
Hypertension ; 80(5): 901-911, 2023 05.
Article en En | MEDLINE | ID: mdl-36748474
Drugs acting by inhibition of the angiogenic action of VEGF (vascular endothelial growth factor) have become major instruments in the treatment of cancer. The downside of their favorable effects in cancer treatment is their frequent cardiovascular side effects. The most consistent finding thus far on the cardiovascular side effects of VEGF inhibitors is the high incidence of hypertension. In this short review, we discuss the evidence that hypertension occurring during VEGF inhibitor treatment is caused by microvascular rarefaction. After a review of the role of VEGF in microvascular growth and differentiation, we present evidence from studies in experimental models of hypertension as well as clinical studies on the microvascular network changes during and after VEGF inhibitor treatment.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Rarefacción Microvascular / Hipertensión / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Hypertension Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Rarefacción Microvascular / Hipertensión / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Hypertension Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos